Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Net Income | -10.66M | -11.14M | -11.79M | -10.92M | -17.84M |
| Total Depreciation and Amortization | 63.00K | 62.00K | 64.00K | 64.00K | 66.00K |
| Total Amortization of Deferred Charges | -- | -- | 146.00K | 146.00K | 146.00K |
| Total Other Non-Cash Items | 2.65M | 2.82M | 2.42M | 1.25M | 8.35M |
| Change in Net Operating Assets | -1.40M | -2.59M | -2.89M | -3.18M | -1.11M |
| Cash from Operations | -9.34M | -10.85M | -12.05M | -12.63M | -10.39M |
| Capital Expenditure | -- | -- | 0.00 | -6.00K | -6.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 0.00 | -6.00K | -6.00K |
| Total Debt Issued | 1.45M | 6.04M | 6.17M | 5.54M | 7.60M |
| Total Debt Repaid | -41.00K | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 3.40M | 5.40M | 5.40M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 5.30M | 3.75M | 3.75M | -- | -- |
| Repurchase of Preferred Stock | -286.00K | -286.00K | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -37.00K |
| Cash from Financing | 6.42M | 9.51M | 13.32M | 10.95M | 12.96M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.92M | -1.34M | 1.27M | -1.69M | 2.57M |
